Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

NCT01359566 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.

NCT NCT01359566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01359566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Lead sponsor
XenoPort, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2011
Completion date
February 28, 2013
Enrollment
228 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis